Associations - Tevimbra (tislelizumab)

No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
PD-L1 overexpression	Urothelial Cancer	PD-L1 overexpression	Urothelial Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
PD-L1 overexpression	Gastric Cancer	PD-L1 overexpression	Gastric Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	tislelizumab Sensitive: A2 - Guideline tislelizumab Sensitive : A2	tislelizumab Sensitive: A2 - Guideline tislelizumab Sensitive : A2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
High 18-gene tumor inflammation signature score	Lung Non-Small Cell Squamous Cancer	High 18-gene tumor inflammation signature score	Lung Non-Small Cell Squamous Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
NOTCH1 mutation	Non Small Cell Lung Cancer	NOTCH1 mutation	Non Small Cell Lung Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
NOTCH2 mutation	Non Small Cell Lung Cancer	NOTCH2 mutation	Non Small Cell Lung Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
NOTCH3 mutation	Non Small Cell Lung Cancer	NOTCH3 mutation	Non Small Cell Lung Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
NOTCH4 mutation	Non Small Cell Lung Cancer	NOTCH4 mutation	Non Small Cell Lung Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	tislelizumab Sensitive: C1 - Off-label tislelizumab Sensitive : C1	tislelizumab Sensitive: C1 - Off-label tislelizumab Sensitive : C1
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: C1 - Off-label tislelizumab Sensitive : C1	tislelizumab Sensitive: C1 - Off-label tislelizumab Sensitive : C1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	tislelizumab Sensitive: C1 - Off-label tislelizumab Sensitive : C1	tislelizumab Sensitive: C1 - Off-label tislelizumab Sensitive : C1
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	tislelizumab Sensitive: C1 - Off-label tislelizumab Sensitive : C1	tislelizumab Sensitive: C1 - Off-label tislelizumab Sensitive : C1
ALK translocation	Non Small Cell Lung Cancer	ALK translocation	Non Small Cell Lung Cancer	tislelizumab Sensitive: C2 – Inclusion Criteria tislelizumab Sensitive : C2	tislelizumab Sensitive: C2 – Inclusion Criteria tislelizumab Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	tislelizumab Sensitive: C2 – Inclusion Criteria tislelizumab Sensitive : C2	tislelizumab Sensitive: C2 – Inclusion Criteria tislelizumab Sensitive : C2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab + pamiparib Sensitive : C2	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab + pamiparib Sensitive : C2
HRD	Ovarian Cancer	HRD	Ovarian Cancer	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab + pamiparib Sensitive : C2	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab + pamiparib Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab + pamiparib Sensitive : C2	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab + pamiparib Sensitive : C2
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab + pamiparib Sensitive : C2	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab + pamiparib Sensitive : C2

Tevimbra (tislelizumab)

Associations
(84)

Associations
(84)

Tevimbra (tislelizumab)

Associations(84)

Associations(84)

Associations
(84)

Associations
(84)